{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:32:22Z","timestamp":1733877142590,"version":"3.30.1"},"reference-count":33,"publisher":"Medknow","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Res Pharm Pract"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/2279-042x.185714","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T08:30:19Z","timestamp":1467880219000},"page":"166","source":"Crossref","is-referenced-by-count":0,"title":["Tenofovir in treatment of Iranian patients with chronic hepatitis B virus infection: An open-label case series"],"prefix":"10.4103","volume":"5","author":[{"given":"Mahsa","family":"Khodadoostan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behrooz","family":"Ataei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babk","family":"Pouria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyman","family":"Adibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2581","reference":[{"key":"key-10.4103\/2279-042X.185714-1","first-page":"97","volume-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"key-10.4103\/2279-042X.185714-2","first-page":"2212","volume-title":"Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"key-10.4103\/2279-042X.185714-3","first-page":"403","volume-title":"The changing epidemiology of viral hepatitis B in Iran","author":"Alavian","year":"2007","journal-title":"J Gastrointestin Liver Dis"},{"key":"key-10.4103\/2279-042X.185714-4","first-page":"245","volume-title":"The prevalence of hepatitis B virus infection in mashhad, iran: A population-based study","author":"Shakeri","year":"2013","journal-title":"Iran Red Crescent Med J"},{"key":"key-10.4103\/2279-042X.185714-5","first-page":"e20540","volume-title":"A population based study on hepatitis B virus in Northern Iran, Amol","author":"Keyvani","year":"2014","journal-title":"Hepat Mon"},{"key":"key-10.4103\/2279-042X.185714-6","first-page":"263","volume-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update","author":"Liaw","year":"2008","journal-title":"Hepatol Int"},{"key":"key-10.4103\/2279-042X.185714-7","first-page":"661","volume-title":"Chronic hepatitis B: Update 2009","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"key-10.4103\/2279-042X.185714-8","first-page":"167","volume-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","author":"European","year":"2012","journal-title":"J Hepatol"},{"key":"key-10.4103\/2279-042X.185714-9","doi-asserted-by":"crossref","unstructured":"Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 2012;142:1360-8.e1.","DOI":"10.1053\/j.gastro.2012.01.044"},{"key":"key-10.4103\/2279-042X.185714-10","first-page":"63","volume-title":"Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B: A systematic review","author":"Buti","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"key-10.4103\/2279-042X.185714-11","first-page":"S174","volume-title":"Antiviral resistance and hepatitis B therapy","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"key-10.4103\/2279-042X.185714-12","first-page":"S185","volume-title":"Side effects of long-term oral antiviral therapy for hepatitis B","author":"Fontana","year":"2009","journal-title":"Hepatology"},{"key":"key-10.4103\/2279-042X.185714-13","first-page":"1218","volume-title":"Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: A systematic review and Bayesian meta-analyses","author":"Woo","year":"2010","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2279-042X.185714-14","first-page":"123","volume-title":"The clinical implications of hepatitis B virus genotype: Recent advances","author":"Lin","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"key-10.4103\/2279-042X.185714-15","first-page":"1206","volume-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.185714-16","first-page":"123","volume-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"key-10.4103\/2279-042X.185714-17","first-page":"2682","volume-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.185714-18","first-page":"1256","volume-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","author":"Dienstag","year":"1999","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.185714-19","first-page":"1001","volume-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.185714-20","first-page":"1011","volume-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.185714-21","first-page":"2576","volume-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.185714-22","first-page":"88","volume-title":"Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis","author":"K\u00f6kl\u00fc","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.4103\/2279-042X.185714-23","first-page":"61","volume-title":"A one-year trial of lamivudine for chronic hepatitis B.Asia Hepatitis Lamivudine Study Group","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.185714-24","first-page":"800","volume-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.185714-25","first-page":"808","volume-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.185714-26","first-page":"2442","volume-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2279-042X.185714-27","first-page":"1240","volume-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2279-042X.185714-28","first-page":"1421","volume-title":"Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection","author":"van","year":"2004","journal-title":"Hepatology"},{"key":"key-10.4103\/2279-042X.185714-29","first-page":"73","volume-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","author":"van","year":"2010","journal-title":"Hepatology"},{"key":"key-10.4103\/2279-042X.185714-30","first-page":"2018","volume-title":"Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B","author":"Murray","year":"2012","journal-title":"Hepatology"},{"key":"key-10.4103\/2279-042X.185714-31","first-page":"505","volume-title":"Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load","author":"Gordon","year":"2013","journal-title":"Hepatology"},{"key":"key-10.4103\/2279-042X.185714-32","first-page":"980","volume-title":"Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B","author":"Fung","year":"2014","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2279-042X.185714-33","first-page":"629","volume-title":"Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA","author":"Gao","year":"2014","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T17:58:02Z","timestamp":1498327082000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrpp.net\/text.asp?2016\/5\/3\/166\/185714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"alternative-id":["185714"],"URL":"https:\/\/doi.org\/10.4103\/2279-042x.185714","relation":{},"ISSN":["2279-042X"],"issn-type":[{"type":"print","value":"2279-042X"}],"subject":[],"published":{"date-parts":[[2016]]}}}